NCT06121011招募中不适用
A Global Prospective Observational Registry of Patients With Pompe Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 500
- 试验地点
- 81
- 主要终点
- Evaluate long-term safety of Pompe disease treatments
研究概览
简要总结
This is a global, multicenter, prospective, observational registry of patients with Pompe disease, including those with late-onset pompe disease (LOPD) and infantile-onset pompe disease (IOPD). Both untreated patients and those being treated with an approved therapy for Pompe disease are eligible to participate.
The objectives of the registry are:
- To evaluate the long-term safety of Pompe disease treatments through collection of data that describe the frequency of adverse events (AEs)/serious adverse events (SAEs) occurring in Pompe disease patients
- To evaluate the long-term real-world effectiveness of Pompe disease treatments
- To evaluate the long-term real-world impact of Pompe disease treatments on quality of life (QOL) and patient-reported outcomes (PROs)
- To describe the natural history of untreated Pompe disease
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of LOPD or IOPD based on documented deficiency of GAA enzyme activity and/or GAA genotyping
排除标准
- •Patients who are currently receiving investigational therapy for Pompe disease in a clinical trial, a compassionate use program, or an expanded access program (EAP)
研究组 & 干预措施
Untreated patients (those who are not currently receiving any medical therapy for Pompe disease)
干预措施: Untreated (Other)
Cipaglucosidase alfa/Miglustat-treated patients
干预措施: Cipaglucosidase alfa (Biological)
Cipaglucosidase alfa/Miglustat-treated patients
干预措施: Miglustat (Drug)
Other Enyzme Replacement Therapy (ERT)-treated patients
干预措施: Alglucosidase alfa or Avalglucosidase alfa (Biological)
结局指标
主要结局
Evaluate long-term safety of Pompe disease treatments
时间窗: 5 years
Data collection that describe the frequency of AEs/SAEs occurring in Pompe disease patients
次要结局
未报告次要终点
研究者
研究点 (81)
Loading locations...
相似试验
招募中
不适用
Pompe Disease Registry ProtocolGlycogen Storage Disease Type IIPompe DiseaseNCT00231400Genzyme, a Sanofi Company2,000
招募中
不适用
Registry for Patients With X-Linked HypophosphatemiaX-Linked HypophosphatemiaNCT03193476Kyowa Kirin Pharmaceutical Development Ltd1,489
招募中
不适用
Lysosomal Acid Lipase (LAL) Deficiency RegistryLysosomal Acid Lipase DeficiencyCholesterol Ester Storage DiseaseWolman DiseaseAcid Cholesteryl Ester Hydrolase Deficiency, Type 2Acid Lipase DeficiencyLIPA DeficiencyLAL-DeficiencyNCT01633489Alexion Pharmaceuticals, Inc.300
已完成
1 期
First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221Pompe DiseaseNCT02675465Amicus Therapeutics32
进行中(未招募)
不适用
Registry for Participants With Short Bowel SyndromeShort Bowel SyndromeNCT01990040Shire1,806
